Evidence map›Paper›PMID 35831850›Full record

Trial reportBMC musculoskeletal disorders2022

Effect of vitamin B6 on pain, disease severity, and psychological profile of fibromyalgia patients; a randomized, double-blinded clinical trial.

Banafsheh Ghavidel-Parsa, Arvin Naeimi, Faeze Gharibpoor, Nazila Sattari, Atefeh Jafari, Irandokht Shenavar Masooleh, Ali Montazeri

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC musculoskeletal disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Banafsheh Ghavidel-ParsaRheumatology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Science, Rasht, Iran.ORCID http://orcid.org/0000-0002-9033-1756
Arvin NaeimiStudent Research Committee, Deputy of Research and Technology, Guilan University of Medical Sciences, Namjoo St, Rasht, 41446-66949, Guilan, Iran.
Faeze GharibpoorStudent Research Committee, Deputy of Research and Technology, Guilan University of Medical Sciences, Namjoo St, Rasht, 41446-66949, Guilan, Iran. faezegharibpoor@gmail.com.
Nazila SattariStudent Research Committee, Deputy of Research and Technology, Guilan University of Medical Sciences, Namjoo St, Rasht, 41446-66949, Guilan, Iran.
Atefeh JafariDepartment of Clinical Pharmacy, School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran.
Irandokht Shenavar MasoolehRheumatology Research Center, Razi Hospital, School of Medicine, Guilan University of Medical Science, Rasht, Iran.
Ali MontazeriPopulation Health Research Group, Health Metrics Research Center, Iranian Institute for Health Sciences Research, ACECR, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGiven the role of vitamin B6 on pronociceptive/antinociceptive neurotransmitters balance, metabolic reactions, and inflammation, it is important to clarify the effect of vitamin B6 on pain and psychological disturbance in fibromyalgia (FM). This study aimed to evaluate whether an 80-mg daily dose of vitamin B6 improves pain, disease severity and psychological symptoms of FM compared to a placebo.

methodsThis randomized, double-blinded, placebo-controlled trial was performed on the FM patients whose diagnosis was confirmed by a rheumatologist based on the 2016 American College of Rheumatology (ACR). 90 Patients were randomized to receive either vitamin B6 (80 mg daily) or placebo in a 1:1 ratio, with a permuted block size of 30 stratified by disease severity. Primary outcomes included the Revised Fibromyalgia Impact Questionnaire (FIQR), Hospital Anxiety and Depression Scale (HADS), 12-item short-form health survey (SF-12), and pain visual analog scale (pain-VAS)). The mean differences in outcomes (before and after treatment) were compared between the vitamin B6 and placebo groups using an independent T-test. An ANCOVA model adjusted for baseline outcome value was also provided to compare the outcomes between the two groups.

resultsOf 90 eligible patients, 60 patients (31 patients in vitamin B6 and 29 in the placebo group) completed the trial. Overall, the FIQR, pain-VAS, and HADS-anxiety scores improved after treatment in both vitamin B6 and placebo groups; However, there was no statistically significant intergroup difference regarding primary outcomes. ANCOVA model also showed no difference in the treatment effects.

conclusionsOur results showed no priority for vitamin B6 over placebo in FM patients. Considering the potential ameliorating role of vitamin B6 on pain and psychological symptoms, acknowledgment of vitamin B6 as a relatively safe adjuvant treatment needs larger future studies.

trial registrationIranian Registry of Clinical Trials: IRCT20200920048782N2 on 2021/10/04.

Indexed as

FibromyalgiaDouble-Blind MethodHumansIranPainSeverity of Illness IndexTreatment OutcomeVitamin B 6Vitamin B 6FibromyalgiaPainPyridoxineVitamin B6

Identifiers

PMID35831850
PMCPMC9277910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.